HCP Connect Clinical Author
Dr. Arjun Sharma
Cardiology
Specialty
Cardiology
Clinical Updates
14
Experience
8 Years
Author Biography
About Dr. Arjun Sharma
Dr. Arjun Sharma is an interventional cardiologist with over 8 years of clinical experience. After completing his MD in General Medicine, he super-specialised with a DM in Cardiology and trained in coronary and structural heart intervention. His interests span acute coronary syndromes, heart failure, and lipid management. He distils evolving trial evidence into practical guidance for practising physicians.
Published Work
Recent Clinical Updates
14 articles
Cardiology
FDA Approves Etripamil for PSVT: 64% 30‑min Conversion in RAPID
Etripamil (Cardamyst) approved for paroxysmal supraventricular tachycardia: 64% 30‑min conversion in RAPID; intranasal 70 mg dose. etripamil paroxysmal supraventricular tachycardia
Cardiology
AZALEA–TIMI 71: Abelacimab Reduced Bleeding Risk (HR 0.38) vs Rivaroxaban in AF
abelacimab atrial fibrillation: AZALEA–TIMI 71 found monthly abelacimab lowered free factor XI and reduced bleeding versus rivaroxaban (HR 0.38; HR 0.31) in AF.
Cardiology
FDA Approves Wegovy for CV Risk in Adults with Obesity: MACE 6.5% vs 8%
semaglutide cardiovascular risk reduction: FDA approved Wegovy to lower major adverse CV events (6.5% vs 8% placebo) in adults with CVD and obesity [9][2].
Cardiology
Dapagliflozin Cuts UACR 29·3% (DAPA-CKD); Empagliflozin: HF and CKD Indications
empagliflozin heart failure: Dapagliflozin reduced UACR 29·3% in DAPA-CKD; empagliflozin (JARDIANCE) is labeled for HF, CKD outcomes and T2D—dose 10 mg daily.
Cardiology
Semaglutide Cuts HF Event Risk 31% in HFpEF (HR 0·69)
Semaglutide reduced the risk of cardiovascular death or first worsening HF event by 31% (HR 0·69) in HFpEF in a pooled analysis of SELECT, FLOW, and STEP-HFpEF trials.
Cardiology
FDA Approves Dapagliflozin for HFpEF: HR 0.82 for Worsening HF or CV Death
Dapagliflozin (Farxiga) FDA approval for heart failure after DELIVER: HR 0.82 for worsening HF or CV death in patients with EF >40% — DELIVER trial data and label updates.
Health Information
Revive Dull Skin in 30 Days with Advanced Techniques
Discover how to restore your glow and boost confidence with proven skincare methods, tackling the top concern of 56% of Gen Y individuals.
Medical Research
Detect Pathogens 50% Faster with RNA Cas12a Assay
Improve disease diagnosis with a sensitive multi-guide RNA Cas12a assay, enabling early intervention and personalized treatment for tuberculosis and other poverty-linked diseases.
Health Information
Vaping vs Smoking: Impact on Dental Health
Learn how vaping and cigarette smoking affect oral hygiene, gum health, and tooth discoloration to better advise your patients on dental care.
Healthcare Business
Boost Arrhythmia Management with Data-Driven Insights
Discover how remote patient monitoring and AI can enhance symptom management, treatment effectiveness, and complication prevention in arrhythmia care.
Medical Research
Reduce Seizures 30% with Precise DBS Targeting
Discover how precise deep brain stimulation targeting can reduce seizures by 30% in patients with drug-resistant epilepsy, offering new hope for improved outcomes.
Medical Research
Gambling Harms Quadruple Youth Suicide Risk
New UK study reveals link between problem gambling and increased suicide risk in young people, with quadrupled risk four years later, informing clinicians on potential intervention...
Medical Research
Delay Hep B Shot to Age 4: Impact on Pediatric Care
Discover the potential benefits of delaying the hepatitis B vaccine until age 4 and its implications for pediatric care and vaccine schedules.
Health Information
Reduce Rheumatoid Arthritis Risk by 60%
Identify 11 key risk factors and take proactive steps to minimize your patients' likelihood of developing rheumatoid arthritis, a potentially disabling autoimmune disease.